Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Nov 08, 2021 3:25pm
136 Views
Post# 34101574

RE:A lot of odd stuff going on

RE:A lot of odd stuff going onWould you need a market support capability for an ATM? It would be awful risky for Cantor to by housing a high risk asset inventory, wouldn't it?  The capital cost would be high unless they know more than we do. I would highly doubt they know more than us.

SPCEO1 wrote: This low volume, $3.50 thing is dfinitely weird. I am sure it will make more sense at some point but it is very odd trading behavior. One theory is that Cantor is holding it there as they expect the ATM to put into action soon and are acquiring shares carefully at this level as part of a market support initiative and to wharehouse them for future selling onto clients once the phase 1a results are out. 

And Leah's name still being on the website is odd too. It is not that hard to fix - so why have they not updated it? 

I suspect there is more going on here than we know. Maybe we will get some hints on Thursday when Paul speaks at Credit Suisse's conference.



<< Previous
Bullboard Posts
Next >>